Abstract
Antiplatelet therapies play a central role in reducing the risk of cardiovascular events such as myocardial infarction and stroke. While aspirin, a cyclo-oxygenase-1 inhibitor has been the cornerstone of antithrombotic treatment for several decades, P2Y12 receptor inhibitors cangrelor, clopidogrel, prasugrel, and ticagrelor and protease-activated receptor-1 antagonist vorapaxar, have emerged as additional therapies to reduce the risk of recurrent cardiovascular events in high-risk patients. Recent clinical trials evaluating the role of these agents and major society guideline updates for use of antiplatelet therapies for secondary prevention of cardiovascular events will be examined. The latest studies regarding the appropriate duration of dual antiplatelet therapy after percutaneous coronary intervention will be presented. The current state of genetic and platelet function testing will be reviewed.
Similar content being viewed by others
References
Go A, Mozaffarian D et al (2013) Heart disease and stroke statistics—2014 update. A report from the American Heart Association. Circulation 129:e28–e292
Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2(1988) ISIS-2 (Second International Study of Infarct Survival) collaborative group. Lancet. 2:349–360
Food and Drug Administration. Center for Drug Evaluation and Research. Application number 204958. FDA Briefing Document for the Cardiovascular and Renal Drugs Advisory Committee. http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/CardiovascularandRenalDrugsAdvisoryCommittee/UCM385234.pdf Accessed 29 Nov 2014
Food and Drug Administration (2014). FDA approves Zontivity to reduce the risk of heart attacks and stroke in high-risk patients. Retrieved from http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm396585.htm
Yusuf S, Zhao F, Mehta SR, Chrolavicius S, Tognoni G, Fox KK (2001) Clopidogrel in unstable angina to prevent recurrent events trial investigators. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 345:494–502
Matetzky S, Shenkman B, Guetta V et al (2004) Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction. Circulation 109:3171–3175
Gurbel PA, Bliden KP, Hiatt BL, O’Connor CM (2003) Clopidogrel for coronary stenting: response variability, drug resistance, and the effect of pretreatment platelet reactivity. Circulation 107:2908–2913
Siller-Matula JM, Trenk D, Schrör K, Gawaz M, Kristensen SD, Storey RF, Huber K, EPA (European Platelet Academy) (2013) Response variability to P2Y12 receptor inhibitors: expectations and reality. JAMA Cardiovasc Interv 6:1111–1128
Ikeda Y, Shimada K, Teramoto T et al (2014) Low-dose aspirin for primary prevention of cardiovascular events in Japanese patients 60 years or older with atherosclerotic risk factors: a randomized clinical trial. JAMA 312(23):2510–2520. doi:10.1001/jama.2014.15690
Bayer (2000) A Study to Assess the Efficacy and Safety of Enteric-Coated Acetylsalicylic Acid in Patients at Moderate Risk of Cardiovascular Disease (ARRIVE). In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). [cited 2014 Nov 27]. Available from: http://clinicaltrials.gov/show/ NCT00501059 NLM Identifier: NCT00501059
University of Oxford (2000) ASCEND: A Study of Cardiovascular Events iN Diabetes. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). [cited 2014 Nov 27]. Available from: http://clinicaltrials.gov/show/ NCT00135226 NLM Identifier: NCT00135226
Minneapolis Medical Research Foundation (2000) Aspirin in Reducing Events in the Elderly (ASPREE). In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). [cited 2014 Nov 27]. Available from: http://clinicaltrials.gov/show/ NCT01038583 NLM Identifier: NCT01038583
Bhatt DL, Lincoff AM, Gibson CM et al (2009) Intravenous platelet blockade with cangrelor during PCI. N Engl J Med 361(24):2330–2341
Harrington RA, Stone GW, McNulty S et al (2009) Platelet inhibition with cangrelor in patients undergoing PCI. N Engl J Med 361:2318–2329
Bhatt DL, Stone GW, Mahaffey KW et al (2013) Effect of platelet inhibition with cangrelor during PCI on ischemic events. N Engl J Med 368:1303–1313
Angiolillo DJ, Firstenberg MS, Price MJ et al (2012) Bridging antiplatelet therapy with cangrelor in patients undergoing cardiac surgery: a randomized controlled trial. JAMA. 307:265–274
Mauri L, Hsieh WH, Massaro JM, Ho KK, D’Agostino R, Cutlip DE (2007) Stent thrombosis in randomized clinical trials of drug-eluting stents. N Engl J Med 356:1020–1029
Levine GN, Bates ER, Blankenship JC et al (2011) 2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions. Circulation 124:e574–e651 (Erratum, Circulation 2012;125(8):e142)
Windecker S, Kolh P, Alfonso F et al (2014) 2014 ESC/EACTS Guidelines on myocardial revascularization: the Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS) developed with the special contribution of the European Association of Percutaneous Cardiovascular Interventions (EAPCI). Eur Heart J 35:2541–2619
Eisenstein EL, Anstrom KJ, Kong DF et al (2007) Clopidogrel use and long-term clinical outcomes after drug-eluting stent implantation. JAMA 297:159–168
Valgimigli M, Campo G, Monti M et al (2012) Short- versus long-term duration of dual-antiplatelet therapy after coronary stenting: a randomized multicenter trial. Circulation 125:2015–2026
Park S-J, Park D-W, Kim Y-H et al (2010) Duration of dual antiplatelet therapy after implantation of drug-eluting stents. N Engl J Med 362:1374–1382
Feres F, Costa RA, Abizaid A et al (2013) Three vs twelve months of dual antiplatelet therapy after zotarolimus-eluting stents: the OPTIMIZE randomized trial. JAMA 310:2510–2522
Mauri L, Kereiakes DJ, Yeh RW et al (2014) Twelve or 30 months of dual antiplatelet therapy after drug-eluting stents. N Engl J Med 371:2155–2166 (Epub 2014 Nov 16)
Schulz-Schüpke S (2014) Randomized, double-blind trial of 6 versus 12 months of dual antiplatelet therapy after DES implantation (ISAR-SAFE). Presented at: American Heart Association Scientific Sessions; Chicago, IL
Gilard M, Barragan P, Noryani AA et al (2014) Six-month versus 24-month dual antiplatelet therapy after implantation of drug eluting stents in patients non-resistant to aspirin: ITALIC, a randomized multicenter trial. J Am Coll Cardiol pii:S0735-1097(14)06970-8. doi:10.1016/j.jacc.2014.11.008 (Epub ahead of print)
O’Gara PT, Kushner FG, Ascheim DD et al (2013) 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 61:485–510
Amsterdam EA, Wenger NK, Brindis RG et al (2014) 2014 AHA/ACC Guideline for the Management of Patients With Non–ST-Elevation Acute Coronary Syndromes: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol pii:S0735-1097(14)06279-2. doi:10.1016/j.jacc.2014.09.017 (Epub ahead of print)
Brener SJ, Oldroyd KG, Maehara A, El-Omar M, Witzenbichler B, Xu K, Mehran R, Gibson CM, Stone GW (2014) Outcomes in patients with ST-segment elevation acute myocardial infarction treated with clopidogrel versus prasugrel (from the INFUSE-AMI trial). Am J Cardiol 113:1457–1460
Henry TD, Peterson E, Cohen D et al (2014) TCT-494 Safety and Effectiveness of Prasugrel vs. Clopidogrel in the Setting of Bivalirudin vs. Heparin Use: 30-day Results from TRANSLATE-ACS. J Am Coll Cardiol 64(11):B145–B146. doi:10.1016/j.jacc.2014.07.548 (ISSN 0735-1097)
Deutsches Herzzentrum Muenchen (2000) Prospective, Randomized Trial of Ticagrelor Versus Prasugrel in Patients With Acute Coronary Syndrome (ISAR-REACT 5). In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). [cited 2014 Nov 28]. Available from: http://clinicaltrials.gov/show/ NCT01944800 NLM Identifier: NCT01944800
Lindholm D, Varenhorst C, Cannon CP, Harrington RA, Himmelmann A, Maya J, Husted S, Steg PG, Cornel JH, Storey RF, Stevens SR, Wallentin L, James SK (2014) Ticagrelor vs. clopidogrel in patients with non-ST-elevation acute coronary syndrome with or without revascularization: results from the PLATO trial. Eur Heart J 35:2083–2093
Montalescot G, van’t Hof AW, Lapostolle F et al (2014) Prehospital ticagrelor in ST-segment elevation myocardial infarction. N Engl J Med 371:1016–1027
AstraZeneca (2000) A Study Comparing Cardiovascular Effects of Ticagrelor and Clopidogrel in Patients With Peripheral Artery Disease (EUCLID). In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). Available from: http://clinicaltrials.gov/ct2/show/NCT01732822 NLM Identifier: NCT01732822
AstraZeneca (2000) Prevention of Cardiovascular Events (eg, Death From Heart or Vascular Disease, Heart Attack, or Stroke) in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin (PEGASUS). In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). Available from: http://clinicaltrials.gov/ct2/show/ NCT01225562 NLM Identifier: NCT01225562
AstraZeneca (2000) SOCRATES -Acute Stroke Or Transient IsChaemic Attack TReated With Aspirin or Ticagrelor and Patient OutcomES. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). Available from: http://clinicaltrials.gov/ct2/show/ NCT01994720 NLM Identifier: NCT01994720
AstraZeneca (2000) A Study Comparing Cardiovascular Effects of Ticagrelor Versus Placebo in Patients With Type 2 Diabetes Mellitus (THEMIS). In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). Available from: http://clinicaltrials.gov/ct2/show/ NCT01991795 NLM Identifier: NCT01991795
AstraZeneca (2014). AstraZeneca announces initiation of development programme for BRILINTA® reversal agent [Press release]. Retrieved from http://www.astrazeneca.com/Media/Press-releases/Article/13112014--astrazeneca-announces-initiation-of-development-progr
Tricoci P, Huang Z, Held C et al (2012) Thrombin-receptor antagonist vorapaxar in acute coronary syndromes. N Engl J Med 366:20–33
Morrow DA, Braunwald E, Bonaca MP et al (2012) Vorapaxar in the secondary prevention of atherothrombotic events. N Engl J Med 366:1404–1413
Valgimigli M, Tricoci P, Huang Z et al (2014) Usefulness and safety of vorapaxar in patients with non-ST-segment elevation acute coronary syndrome undergoing percutaneous coronary intervention (from the TRACER Trial). Am J Cardiol 114:665–673
Collet JP, Hulot JS, Pena A et al (2009) Cytochrome P450 2C19 polymorphism in young patients treated with clopidogrel after myocardial infarction: a cohort study. Lancet 373:309–317
Hulot JS, Collet JP, Cayla G et al (2011) CYP2C19 but not PON1 genetic variants influence clopidogrel pharmacokinetics, pharmacodynamics, and clinical efficacy in post-myocardial infarction patients. Circ Cardiovasc Interv 4:422–428
Mega JL, Close SL, Wiviott SD, Shen L, Hockett RD, Brandt JT, Walker JR, Antman EM, Macias WL, Braunwald E, Sabatine MS (2009) Cytochrome P450 genetic polymorphisms and the response to prasugrel: relationship to pharmacokinetic, pharmacodynamic, and clinical outcomes. Circulation 119:2553–2560
Wallentin L, James S, Storey RF et al (2010) Effect of CYP2C19 and ABCB1 single nucleotide polymorphisms on outcomes of treatment with ticagrelor versus clopidogrel for acute coronary syndromes: a genetic substudy of the PLATO trial. Lancet 376(9749):1320–1328
Collet JP, Cuisset T, Rangé G et al (2012) Bedside monitoring to adjust antiplatelet therapy for coronary stenting. N Engl J Med 367:2100–2109
Price MJ, Berger PB, Teirstein PS et al (2011) Standard- vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: the GRAVITAS randomized trial. JAMA 305:1097–1105
Trenk D, Stone GW, Gawaz M et al (2012) A randomized trial of prasugrel versus clopidogrel in patients with high platelet reactivity on clopidogrel after elective percutaneous coronary intervention with implantation of drug-eluting stents: results of the TRIGGER-PCI (Testing Platelet Reactivity In Patients Undergoing Elective Stent Placement on Clopidogrel to Guide Alternative Therapy With Prasugrel) study. J Am Coll Cardiol 59:2159–2164
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Yang, E. Current antiplatelet agents: place in therapy and role of genetic testing. J Thromb Thrombolysis 39, 328–336 (2015). https://doi.org/10.1007/s11239-015-1195-5
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11239-015-1195-5